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Intracellular signals triggered by DNA breakage flow
through proteins containing BRCT (BRCA1 C-termi-
nal) domains. This family, comprising 23 conserved
phosphopeptide-binding modules in man, is inac-
cessible to small-molecule chemical inhibitors.
Here, we develop Bractoppin, a drug-like inhibitor
of phosphopeptide recognition by the human
BRCA1 tandem (t)BRCT domain, which selectively
inhibits substrate binding with nanomolar potency
in vitro. Structure-activity exploration suggests that
Bractoppin engages BRCA1 tBRCT residues recog-
nizing pSer in the consensus motif, pSer-Pro-Thr-
Phe, plus an abutting hydrophobic pocket that is
distinct in structurally relatedBRCTdomains, confer-
ring selectivity. In cells, Bractoppin inhibits substrate
recognition detected by Fo¨rster resonance energy
transfer, and diminishes BRCA1 recruitment to DNA
breaks, in turn suppressing damage-induced G2
arrest and assembly of the recombinase, RAD51.
But damage-induced MDC1 recruitment, single-
stranded DNA (ssDNA) generation, and TOPBP1
recruitment remain unaffected. Thus, an inhibitor of
phosphopeptide recognition selectively interrupts
BRCA1 tBRCT-dependent signals evoked by DNA
damage.
INTRODUCTION
BRCT domains, first described as a discrete structural motif en-
coded in the C-terminal region of the breast and ovarian cancer
suppressor protein, BRCA1, represent a widely distributed fam-
ily (PFAM PF00533) of modules that mediate protein-protein in-
teractions involved in the recognition of phosphopeptides
(Bork et al., 1997; Koonin et al., 1996; Manke et al., 2003; Yu
et al., 2003). BRCT domains with evolutionarily conserved se-Cell Chemical Biology 25, 1–1
This is an open access article undquences have been identified across all kingdoms of life, where
they form functionally critical elements of proteins, which partic-
ipate in the signaling pathways that preserve genome integrity,
through functions in DNA replication and repair (reviewed in Gerl-
off et al., 2012; Leung and Glover, 2011; Mesquita et al., 2010).
While the human proteome encodes 23 different BRCT-contain-
ing proteins (Woods et al., 2012), over 245 have been identified in
other species.
Twelve of the human proteins containing BRCT domains
incorporate more than one copy of the 100-residue BRCT
domain fold, comprising a four-stranded b sheet juxtaposed to
three a-helical regions in the order babbaba (Williams et al.,
2001). In human BRCA1, two BRCT domain folds pack tightly
to one another in a head-to-tail orientation, illustrating a sub-
group of tandem BRCT (tBRCT) domains that includes the
tBRCT domains of the human proteins DNA topoisomerase
2-binding protein 1 (TOPBP1), mediator of DNA damage check-
point 1 (MDC1) and microcephalin 1 (MCPH1) (reviewed in Gerl-
off et al., 2012; Leung and Glover, 2011; Mesquita et al., 2010).
The BRCA1 tBRCT domain binds phosphorylated peptides
with the consensus sequence, pSer-Pro-Thr-Phe, wherein the
first and last residues are highly conserved, but amino acid rep-
resentation in the intervening residues exhibits less stringency
(i.e., pSer-X-X-Phe) (Manke et al., 2003; Rodriguez et al., 2003;
Yu et al., 2003). Structural analysis of the complex between
BRCA1 tBRCT and the consensus phosphopeptide from the
DNA helicase, BTB domain and CNC homolog 1 (BACH1) re-
veals that the phosphopeptide sits in a cleft formed between
the tightly packed tBRCT folds. While the conserved pSer resi-
due contacts the polar side chains of Ser1655 and Lys1702
from just one BRCT fold, the Phe residue engages a hydrophobic
pocket formed by the side chains of Met1775, Phe1704,
Arg1699, and Leu1839 from both of them (Clapperton et al.,
2004; Shiozaki et al., 2004; Williams et al., 2004). These contacts
‘‘anchor’’ the phosphopeptide within the binding cleft.
Genetic and biochemical evidence implicates the human
BRCA1 tBRCT domain in the recruitment of BRCA1 to cellular
sites of DNA damage marked by phosphorylated (g) histone
H2AX, via an interaction of the tBRCT domain with a pSer residue
on the adaptor protein ABRAXAS (Wang et al., 2007). In turn,4, June 21, 2018 ª 2018 The Authors. Published by Elsevier Ltd. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Structure-Activity Relationships of Compounds Inhibiting Phosphopeptide Recognition by the BRCA1 tBRCT
(A) Structure of CCBT002, an inhibitor of phosphopeptide recognition by the BRCA1 tBRCT, identified by screening a 128,000-element compound library.
(B) Dose-response and selectivity profile for CCBT002. The compound’s ability to inhibit the recognition of cognate biotinylated phosphopeptides to the BRCA1
tBRCT, TOPBP1 tBRCT 7/8, or GRB2 SH2 proteins was measured using an AlphaScreen assay. Percent inhibition is plotted against compound concentration.
(C) Structure of a BACH1 phosphopeptide (cyan sticks) bound to BRCA1 tBRCT (PDB: 3KOK). Yellow or gray shading marks each of the tBRCT modules. Water
molecules are red spheres.
(D) Predicted binding mode of CCBT002 (green sticks) in BRCA1 tBRCT. Dotted lines mark hydrogen bonds.
(E) Chemical modifications testing the predicted structure-activity relationships of CCBT002. Structures of CCBT002 analogs are shown in the top panel, with
substitutions made at positions R1, R2, or R3 in the central column. The final column shows the IC50 value for each compound to competitively inhibit the binding
of BACH1 phosphopeptide to BRCA1 tBRCT as measured by MST (NB, no binding). Bractoppin (IC50 = 0.074 mM) is marked in red. An inactive analog,
CCBT2047, exhibits no binding detectable in this assay. Experiments show the mean ± SD of three independent experiments.
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of a macromolecular complex nucleated around BRCA1, which
mediates multiple intracellular signals that choreograph events
during the DNA damage response (DDR). BRCA1 coordinates
three key limbs of the DDR by engaging the claspin-CHK1 com-
plex to activate the G2 cell-cycle checkpoint for DNA damage
(Kumagai and Dunphy, 2000; Sato et al., 2012; Yarden et al.,
2002), an endonuclease complex containing CtIP that resects2 Cell Chemical Biology 25, 1–14, June 21, 2018double-stranded DNA dsDNA) to generate overhanging ssDNA
substrates (You et al., 2009; Yu et al., 1998), and a DNA recom-
bination complex containing the recombinase RAD51 to localize
it to sites of DNA breakage (Bhattacharyya et al., 2000; Scully
et al., 1997).
Accordingly, there is considerable current interest in devel-
oping selective small-molecule inhibitors that modulate phos-
phopeptide substrate recognition by the BRCT domain family,
Figure 2. Bractoppin, a Drug-like Inhibitor of Phosphopeptide
Recognition by the BRCA1 tBRCT
(A) Competitive inhibition by Bractoppin or its inactive analog CCBT2047 of the
binding of BACH1 phosphopeptide to BRCA1 tBRCT measured by MST.
Compound concentration in nM is plotted on the x axis, against changes in
normalized fluorescence (DFnorm), on the y axis. Plots represent themean ± SD
(error bars) from three independent experiments. The calculated IC50 for
Bractoppin is shown.
(B) Predicted binding mode of Bractoppin (orange sticks) in BRCA1 tBRCT
(transparent surface). Yellow or gray surface distinguishes each of the BRCT
modules. Dotted lines mark hydrogen bonds.
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the proteins containing them. Gossypol, a phenolic natural prod-
uct with promiscuous biological activities, includingmale contra-
ception, besides human toxicities, is reported to bind the BRCT
domain of poly-ADP ribose polymerase (Na et al., 2015). Peptidic
inhibitors of phosphopeptide recognition by the BRCA1 tBRCT
(Yuan et al., 2011), including cell-permeant dipeptidic variants
incorporating a non-hydrolysable difluoromethylene-substituted
phospho-Ser moiety (Na et al., 2014), have been reported. How-
ever, their physico-chemical characteristics, and the paucity of
information concerning the selectivity of their biological effects,
render further development difficult. Thus, the BRCT domain
family currently remains inaccessible to selective, drug-like,
small-molecule inhibitors.
Here, we report the development of Bractoppin, a drug-like
inhibitor of phosphopeptide recognition by the human BRCA1tBRCT domain. We have explored its structure-activity relation-
ships, exposing contacts that confer activity, as well as its
selectivity against structurally related members of the BRCT
domain family, suggesting a blueprint for further development.
Bractoppin engages its target in cells, inducing character-
istic biological effects that discriminate BRCA1-dependent
signaling events during the human DDR. Our work provides a
template for the future development of drug-like inhibitors
against the BRCT domain family, and exemplifies a strategy
to selectively modulate intracellular signal transduction by pro-
tein kinases by blocking the recognition of their phosphopep-
tide substrates.
RESULTS
Development and Structure-Activity Relationships of
Bractoppin, a Drug-like Inhibitor of Phosphopeptide
Binding by BRCA1 tBRCT
We screened a diversity library of 128,000 drug-like molecules
(Huggins et al., 2011) using a fluorescence polarization assay
(Figures S1A–S1C) to identify compounds that inhibit the binding
of the human BRCA1 tBRCT to a TAMRA-labelled phosphopep-
tide from BACH1. A hit identified in the screen (4-(2-fluoroben-
zyl)-2-isopropylpiperazin-1-yl) (2-methyl-1H-benzo[d]imidazol-
5-yl)methanone, CCBT002 (Figure 1A) is a 394-Da compound
that contains no obvious chemical toxicophores or reactive
groups, and therefore was regarded as a suitable starting point
for development. This compound comprises a 2-isopropyl piper-
azine core, attached via a carbonyl linkage to benzimidazole ring
on nitrogen N1, with an o-fluoro benzyl moiety on nitrogen N4.
The enantiomeric form of the isopropyl group in CCBT002 was
not established. CCBT002 was validated in a homogeneous
AlphaScreen assay (Figure S1D) designed to measure its capac-
ity to displace cognate phosphopeptides either from the human
BRCA1 tBRCT, or as controls, from the growth factor receptor-
bound protein 2-Src-homology (GRB2-SH2) domain (Nioche
et al., 2002) (a pTyr-binding domain structurally distinct from
BRCT) or the TOPBP1 tBRCT 7/8 domain (Leung et al., 2011)
(structurally a close relative of the BRCA1 tBRCT). CCBT002
competitively inhibits the binding of cognate phosphopeptide
to the human BRCA1 tBRCT with a half maximal inhibitory con-
centration (IC50) of 47.3 mM, but not to the GRB2-SH2 domain or
the TOPBP1 tBRCT domain (Figure 1B). These findings suggest
that CCBT002 has features of a selective, drug-like inhibitor of
phosphopeptide recognition by the BRCA1 tBRCT.
We combined computational chemistry with the synthesis and
testing of new compounds to explore and experimentally vali-
date the structure-activity relationships of CCBT002, because
its limited solubility in aqueous buffers impeded our attempts
to determine its structure bound to the BRCA1 tBRCT using
X-ray crystallography. As indicated by prior crystallographic re-
ports (Clapperton et al., 2004; Shiozaki et al., 2004; Williams
et al., 2004), substrate binding to BRCA1 tBRCT does not induce
major changes in the phosphopeptide-binding site (Figure S1E).
Accordingly, we predicted potential bindingmodes for CCBT002
by molecular docking at the phosphopeptide-binding site (Fig-
ure 1C) using Glide (Schro¨dinger Release, 2015-3, 2015).
Different ionization, tautomeric, and chiral states of CCBT002
were considered (Schro¨dinger Release, 2015-3: LigPrep,Cell Chemical Biology 25, 1–14, June 21, 2018 3
Figure 3. Selectivity of Bractoppin against Structurally Related BRCT Domains
(A–D) Bractoppin (orange) ismodeled on the structurally related human BRCT domains of (A) MCPH1 2/3 (PDB: 3SZM), (B) TOPBP1 7/8 (PDB: 3AL3), (C) ECT2 1/2
(PDB: 4N40), and (D) TOPBP1 1/2 (PDB: 3OLC). Each tBRCT domain was aligned to BRCA1 tBRCT’s phosphopeptide-binding pocket. Key residues are shown in
sticks. Note the differences between these tBRCT domains and BRCA1 tBRCT (Figure 2B) in contacts made by the phenyl ring on the left-hand side of Brac-
toppin. Also, contacts made by the fluorobenzyl moiety on the right-hand side of Bractoppin are absent in the ECT2 and TOPBP1 1/2 tBRCT domains.
(E) Selectivity profile for Bractoppin as measured by competitive MST assay. Bractoppin concentration in nM is plotted on the x axis, against changes in
normalized fluorescence (DFnorm), on the y axis. The plot shows the mean ± SD of three independent experiments.
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to its shallow pocket. Binding modes were evaluated by short,
2-ns molecular dynamics simulations (Bharatham et al., 2017)
to identify a stable binding mode (Figure S1F). This predicted
binding mode (Figure 1D) shows that CCBT002 recapitulates in-
teractions made in BRCA1 tBRCT by the consensus phospho-
peptide pSer-Pro-Thr-Phe, capturing not only polar contacts
made in the pSer-recognizing pocket, but, in addition, making
a novel contact in a hydrophobic pocket at the interface between
the tBRCT folds. Thus, the unsaturated nitrogen, N3 of the benz-4 Cell Chemical Biology 25, 1–14, June 21, 2018imidazole core of CCBT002 makes a hydrogen-bonding interac-
tion with the Lys1702 side-chain amine and the carbonyl inter-
acts with the backbone amine group of Lys1702 and Leu1701
in BRCA1 tBRCT. The backbone nitrogens of Leu1701 and
Lys1702 act as H-bond donors to contact water molecules
observed in several crystal structures of BRCA1 tBRCT (e.g.,
Leung et al., 2011). The CCBT002 carbonyl group displaces
the water while maintaining interactions with these residues.
The o-fluoro-benzyl group is partially surrounded by a hydropho-
bic groove formed between the two BRCT domains, making
Figure 4. Bractoppin Inhibits Substrate Recognition by the BRCA1 tBRCT in the Cellular Milieu
(A) Schematic depicting the unimolecular FRET biosensor. The BACH1 sequence (yellow box) is phosphorylated by intracellular kinases, triggering engagement
by BRCA1 tBRCT (red semi-circle), and inducing FRET by apposition of Tag-BFP and Tag-GFP2 fluorophores. FRET is diminished when compounds or over-
expression of BRCA1 tBRCT domain competitively inhibit Tag-BFP phospho-BACH1/Tag-GFP2 BRCA1 tBRCT binding.
(B) Validation of unimolecular FRET biosensor. Fluorescence emission at 420–600 nm wavelengths was measured in HEK293 cells expressing tetracycline (Tet)-
inducible biosensor constructs. Constructs encoding Tag-BFP (excited at 402 nm) or Tag-GFP2 (excited at 483 nm) alone were used for spectral correction.
Normalized fluorescence intensities are plotted against wavelength. Fluorescence emission is shown for the unimolecular FRET biosensor (red line) or its S990A
mutant form (black line) excited at 402 nm 24 hr after the exposure of cells to 16 Gy irradiation.
(C) Effect of Bractoppin or its inactive analog CCBT2047 on FRET measured by sensitized emission. The first panel on the left shows changes in FRET efficiency
(mean ± SEM) in biosensor-expressing cells 24 hr after transient transfection with a construct encoding BRCA1 tBRCT, which is expected to competitively inhibit
phospho-BACH1/BRCA1 tBRCT binding in the biosensor. The second panel plots FRET efficiency as a dot plot in which each dot representsmeasurements from
a single cell (n = 60, control, or 70, tBRCT). The third and fourth panels show the corresponding FRET measurements after the exposure of cells to 0.5% DMSO
(vehicle control), 100 mMBractoppin, or 100 mMCCBT2047 for 24 hr (n = 640, DMSO; 400, Bractoppin; 650, CCBT2047). Statistical significance was tested using
an unpaired, two-tailed t test. ***p% 0.001.
(legend continued on next page)
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isopropyl group on the piperazine ring projects toward the Phe
binding pocket making weak hydrophobic interactions with
Leu1701 and Met1775 side chains and therefore is predicted
to be preferred over the R-enantiomer. To experimentally vali-
date the predicted binding mode, we synthesized compounds
(Figure 1E) designed to challenge the expected interactions of
CCBT002, and tested their ability to competitively inhibit the
binding of a phosphorylated BACH1 substrate peptide to
BRCA1 tBRCT using microscale thermophoresis (MST) (Seidel
et al., 2013) (Figures S1G and S1H).
CCBT2906, which represents the S-enantiomeric form of the
isopropyl group, exhibits stronger activity (IC50 = 1.7 mM) than
the R-enantiomer (CCBT2905, IC50 = 56 mM) or a compound
lacking the isopropyl group altogether (CCBT2907, IC50
53 mM, estimated value owing to non-saturability of binding).
Thus, the isopropyl group makes a significant contribution to
overall affinity, and its S-enantiomer is preferred, as expected
from the predicted bindingmode. Removal of the carbonyl group
(CCBT2908) renders the compound inactive, consistent with the
critical role proposed for this group in contacting the BRCA1
tBRCT residues that recognize pSer. Finally, substitution of the
benzimidazole with indole (CCBT2029) reduces affinity, consis-
tent with the predicted role of the benzimidazole nitrogen, N3.
Thus collectively, our findings provide evidence to validate
the predicted binding mode for CCBT002, and, in particular,
to corroborate key contacts made by the benzimidazole nitro-
gen, N3, and carbonyl with the pSer-recognizing pocket in
BRCA1 tBRCT.
To optimize potency, we next explored modifications (Fig-
ure 1E) on the left-hand side (LHS) or right-hand side (RHS) of
the core structure validated in the experiments above. LHSmod-
ifications were designed to capture additional contacts––not
made by the cognate phosphopeptide––in the hydrophobic cav-
ity abutting the pSer-recognition pocket that is formed by
Phe1662, Leu1657, Val1654, and Pro1659 residues of BRCA1
tBRCT. Substitution of the methyl group (R1) with somewhat
bulkier or flexible moieties––either isopropyl (CCBT2009) or mor-
pholinyl (CCBT2084)––abrogated activity. However, introduction
of a rigid phenyl group at R1 yielded a compound (Bractoppin)
with nanomolar activity (IC50 = 0.074 mM).
Bractoppin (Figure 1E) is a 414-Da compound, with nanomolar
potency in displacing cognate BACH1 phosphopeptide sub-
strate from the BRCA1 tBRCT as measured by MST (Figure 2A).
Its predicted binding mode to BRCA1 tBRCT (Figure 2B) reveals
favorable hydrophobic interactions in the hydrophobic cavity, as
well as a T-shaped, pi-pi stacking interaction with Phe1662, that
together significantly contribute toward its activity. Indeed, sub-
stitution of the phenyl ring at R1 in Bractoppin with a 4-pyridyl
group (CCBT2082) decreased activity by 5-fold by affecting
the stacking interaction with Phe1662.
On the RHS of Bractoppin, the benzene ring of the benzyl
group situated at the interface between the two BRCT folds ap-
pears critical for activity, because its modification to iso-butyl(D) Effect of Bractoppin or its inactive analog CCBT2047 on FRET measured by a
FRET efficiency after transient transfection with BRCA1 tBRCT, or exposure to D
(n = 60, control; 40, tBRCT; 380, DMSO; 370, Bractoppin). FRET efficiency was nor
bottom). Statistical significance was tested using an unpaired, two-tailed t test. *
6 Cell Chemical Biology 25, 1–14, June 21, 2018(CCBT2047) abolishes activity. Substitutions at the para-position
of the benzyl ring, including hydroxyl (CCBT2106, IC50 = 3.6 mM)
or methyl (CCBT2107, IC50 = 0.3 mM) groups, reduced activity
indicating that the para-position prefers hydrophobic over polar
groups, as predicted in the binding mode. Thus, collectively, our
findings identify Bractoppin as a potent inhibitor of phosphopep-
tide recognition by the BRCA1 tBRCT, and provide multiple lines
of evidence to support its predicted bindingmode and structure-
activity relationships.
Selectivity of Bractoppin against Structurally Related
tBRCT Domains
The predicted binding mode for Bractoppin in BRCA1 tBRCT
suggests a structural rationale for its potential selectivity against
other related human tBRCT domains, assuming that the com-
pound binds in a similar orientation at their respective phospho-
peptide binding sites. These include the tBRCT domains from
MCPH1, TOPBP1, and epithelial cell transforming 2 (ECT2).
TOPBP1 contains multiple BRCT modules, of which BRCT7
andBRCT8 are arranged in a tandemhead-to-tail array (TOPBP1
7/8) that structurally resembles the BRCA1 tBRCT (Leung and
Glover, 2011), as are the tBRCT domains from MCPH1 (Shao
et al., 2012; Singh et al., 2012). In contrast, the BRCT folds
comprising the tBRCT domains of ECT2 (Zou et al., 2014) or
TOPBP1 1/2 (Rappas et al., 2011) are rotated by90 compared
with the BRCA1 tBRCT, such that they assume a perpendicular
orientation to one another.
The phenyl ring decorating the LHS of Bractoppin captures
contacts in a hydrophobic cavity formed by BRCA1 tBRCT
residues Phe1662, Leu1657, Val1654, and Pro1659 (Fig-
ure 2B). This hydrophobic cavity is distinct from other tBRCT
domains, including those of MCPH1, TOPBP1 7/8, ECT2, or
TOPBP1 1/2, owing to differences in its lining residues (Fig-
ures 3A–3D). Moreover, contacts made in BRCA1 tBRCT
with the fluorobenzyl moiety on the RHS of Bractoppin are ab-
sent in the ECT2 and TOPBP1 1/2 tBRCT domain, owing to
changes in the orientation between the BRCT modules
compared with BRCA1 tBRCT. Consistent with the predicted
structural rationale for selectivity, Bractoppin does not detect-
ably bind to fluorescently labeled tBRCT domains from
MCPH1, TOPBP1 7/8, ECT2, or TOPBP1 1/2 as measured
by competitive MST (Figure 3E). Thus, collectively, our find-
ings validate and provide a structural rationale for the selec-
tivity of Bractoppin against several related tBRCT domains
from human proteins.
Bractoppin Inhibits Substrate Recognition by theBRCA1
tBRCT in Cells
Wedeployed a genetically encoded, unimolecular biosensor that
exploits Fo¨rster resonance energy transfer (FRET) to detect
intracellular target engagement by Bractoppin. The biosensor
comprises the BRCA1 tBRCT, amino N-terminally fused to the
fluorophore monomeric GFP (Tag-GFP2), and connected to a
blue fluorescent protein (Tag-BFP) via a 16-residue sequencecceptor photobleaching. As above, the first panel on the left shows changes in
MSO or Bractoppin, while the central panel plots FRET efficiency as a dot plot
malized to bleach efficiency in each experiment (final panel on the right, top and
**p% 0.001. Similar results were observed in four independent repeats.
Figure 5. Bractoppin Selectively Inhibits Cellular Substrate Recognition by the tBRCT Domain Family
(A) Confocal images depicting at high magnification (1893) the recruitment of the BRCA1 protein into nuclear foci after the indicated treatments (untreated cells
[0 Gy]; irradiation alone [16 Gy]; Tet-induced BRCA1 tBRCT expression 30 hr before irradiation; 100 mM Bractoppin or its inactive analog CCBT2047 added 6 hr
after irradiation). Staining 18 hr after irradiation in the upper row is for BRCA1 (green), middle row, for mCherry-BRCA1 tBRCT (red); lower row, merged red and
green staining, with DNA staining (DAPI) in blue. Scale bar represents 10 mm.
(legend continued on next page)
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phorylated by intracellular protein kinases, it is recognized by
the BRCA1 tBRCT, apposing the Tag-BFP and Tag-GFP2 re-
porters to induce FRET. HEK293 cells were stably transfected
with a construct encoding the biosensor under the control of a
tetracycline-inducible promoter. Constructs encoding Tag-BFP
or Tag-GFP2 alone were used as controls for spectral correction
to calculate FRET efficiency. For validation, we first exposed
cells stably expressing the biosensor to 16 Gy ionizing radiation
(IR), which is reported to activate signals leading to BACH1
phosphorylation (Peng et al., 2006; Shiozaki et al., 2004). Indeed,
this suffices to induce FRET (Figure 4B). FRET is abrogated (Fig-
ure 4B) by the replacement of the Ser residue in the BACH1
substrate peptide that undergoes phosphorylation, with the
non-phosphorylable residue, Ala (Ser990Ala biosensor), con-
firming the specificity of pSer recognition by the BRCA1 tBRCT
in the biosensor construct.
Overexpression of a construct encoding the BRCA1 tBRCT
domain––which is expected to mimic the cellular effects of Brac-
toppin by competitively inhibiting phosphopeptide substrate
recognition––suffices to decrease FRET efficiency detected by
the biosensor, as measured by sensitized emission (Figure 4C)
or acceptor photobleaching (Figure 4D). Notably, Bractoppin–
but not its inactive iso-butyl substituted analog, CCBT2047––
also inhibits FRET (Figures 4C, 4D, and S2).
Bractoppin Selectively Inhibits Cellular Substrate
Recognition by the BRCA1 but Not MDC1 tBRCT
Following exposure to IR, BRCA1 protein is recruited to cellular
sites of DNA damage, where it assembles in microscopic foci,
through the recognition of a phosphorylated motif in the adaptor
protein ABRAXAS via the BRCA1 tBRCT (Wang et al., 2007; Wu
et al., 2016). Again, overexpression of the BRCA1 tBRCT
domain, but neither the tBRCT M1775R nor S1655A/K1702M
mutant forms deficient in phosphopeptide substrate binding,
decreases BRCA1 foci formation following DNA damage as
measured by high-content microscopy using a murine mono-
clonal antibody against BRCA1 (Figures S3A–S3C). Bractoppin,
but not its inactive analog, CCBT2047, also inhibits the formation
of radiation-induced BRCA1 foci (Figures 5A and 5B). Similar re-
sults were observed in a different cell line using an alternative
monoclonal antibody directed against a distinct BRCA1 epitope
(Figure S3D).
The human protein MDC1 is also recruited to microscopic
foci formed at sites of DNA damage through interactions medi-
ated by its tBRCT domains (Lou et al., 2003; Stewart et al.,
2003; Stucki et al., 2005). While the MDC1 tBRCT domain is
structurally related to that of BRCA1 (Campbell et al., 2010),
the extent of substrate cross-recognition by these tBRCT
domain family members remains unclear. In turn, given the po-
tential for substrate cross-recognition in the cellular milieu,(B) Percentage of cells positive for radiation-induced nuclear BRCA1 foci (mean
toppin; 13,000, CCBT2047) enumerated by high-content imaging at low magnific
Statistical significance was determined using an unpaired two-tailed t test. ***p%
(C) Percentage of cells positive for radiation-induced nuclear MDC1 foci (mean ±
4,600, CCBT2047) enumerated as above. Treatment conditions were as describ
tested. Statistical significance was determined using an unpaired two-tailed t tes
(D) Cells treated as in (C) were stained for nuclear BRCA1 foci. Similar results we
8 Cell Chemical Biology 25, 1–14, June 21, 2018whether drug-like inhibitors of substrate recognition by tBRCT
can elicit selective biological effects is uncertain. To test this
issue, we first determined the effects of MDC1 tBRCT overex-
pression on the formation of damage-induced MDC1 or BRCA1
foci in cells (Figures 5C and 5D). As expected, MDC1 tBRCT
suppresses both MDC1 and BRCA1 foci formation, since
MDC1 recruitment to damage sites precedes and is required
for BRCA1 accumulation (Huen et al., 2007; Kolas et al.,
2007; Mailand et al., 2007). Interestingly, however, Bractoppin,
but not its inactive analog CCBT2047, selectively inhibits dam-
age-induced BRCA1 foci formation, but has little effect on the
radiation-induced accumulation of MDC1 at sites of DNA dam-
age (Figures 5C, 5D, and S3E). Similarly, Bractoppin has little
effect on the radiation-induced recruitment of TOPBP1 (Fig-
ure S3F), a protein containing multiple, structurally related
tBRCT domains, again speaking to the selectivity of its effects.
Thus, collectively, our observations provide multiple lines of
evidence that Bractoppin selectively inhibits the recognition of
phosphopeptide substrates by the human BRCA1 tBRCT, sup-
pressing the recruitment of BRCA1, but not other proteins con-
taining structurally related tBRCT domains, to cellular DNA
damage sites.
Bractoppin Interrupts DNA Damage Signaling for G2
Arrest
BRCA1 recruitment to sites of DNAdamage initiates events lead-
ing to cell-cycle arrest at the G2 checkpoint (Yarden et al., 2002;
Yu and Chen, 2004). Overexpression of the BRCA1 tBRCT in-
hibits damage-induced G2 arrest (Figures 6A and 6B), whereas
the single (M1775R) and the double (S1655A, K1702M) tBRCT
mutants do not (Figures S4A–S4D). G2 arrest is also inhibited
in a dose-dependent manner by Bractopppin, but not by its inac-
tive analog CCBT2047 (Figures 6A and 6B), suggesting that the
compound interrupts signals that activate the G2 checkpoint.
Failure to engage the G2 checkpoint sensitizes cells to the cyto-
toxic effects of IR (Tenzer and Pruschy, 2003). Indeed, overex-
pression of the BRCA1 tBRCT significantly enhances cytotox-
icity induced by exposure to 1 Gy IR, as does treatment with
Bractoppin in a dose-dependent manner (Figure 6C). Together,
these findings demonstrate that Bractoppin inhibits intracellular
signals essential for the response of human cells to DNA
damage.
Bractoppin Discriminates BRCA1-Dependent Steps in
DNA Repair by Homologous Recombination
IR-induced double-strand DNA breaks are repaired in dividing
cells by homologous DNA recombination (HR), a mechanism in
which BRCA1, and the related tumor suppressor protein
BRCA2, have been implicated at several steps (reviewed in Ven-
kitaraman, 2014). HR is initiated by the resection of DNA ends to
generate ssDNA tracts that are coated by the ssDNA-binding± SD; n = 15,000, 0 Gy, 20,000, 16 Gy; 10,500, BRCA1 tBRCT; 10,600, Brac-
ation (see the STAR Methods). Treatment conditions were as described in (A).
0.001. Similar results were observed in three independent repeats.
SD; n = 24,000, 0 Gy; 6,000, 16 Gy; 14,500, MDC1-tBRCT; 8,000, Bractoppin;
ed in (A), except that the effect of Tet-induced MDC1 tBRCT expression was
t. ***p% 0.001; ns, not significant.
re observed in three independent repeats. **p% 0.01; ***p% 0.001.
Figure 6. Bractoppin Interrupts DNA Damage Signaling for G2 Arrest
(A) Representative histograms of cell-cycle distribution measured by flow cytometry after DAPI staining. Cells were irradiated with 4 Gy at 8 hr after synchronous
release into the cell cycle from thymidine block, and measurements made 16 hr later. The histograms show unirradiated cells (Control), or cells exposed to 4 Gy,
with or without additional treatments using Tet-inducible BRCA1 tBRCT expression, 10–100 mM Bractoppin or 100 mM CCBT2047. Tet-induced BRCA1 tBRCT
expression was for 32 hr before radiation, while compoundswere added 0.5 hr before. A total of 15,000 cells were analyzed per condition, in replicates of 3 (green,
G1, yellow, S, blue, G2/M).
(legend continued on next page)
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Gautier, 2011). These ssDNA tracts not only stimulate the activa-
tion of the G2 checkpoint via the ATR-ATRIP complex (Kumagai
et al., 2006; Zou and Elledge, 2003), but also serve as substrates
for the formation of ordered nucleoprotein assemblies contain-
ing the recombination enzyme, RAD51 (reviewed in San Filippo
et al., 2008). While genetic studies suggest that BRCA1 is essen-
tial to signal G2 arrest, and recruit RAD51 to DNA damage sites,
DNA end-resection and the accumulation of RPA can proceed
through BRCA1-dependent as well as BRCA1-independent
mechanisms (Cruz-Garcı´a et al., 2014; Polato et al., 2014; Re-
czek et al., 2013). Indeed, Bractoppin selectively suppresses
IR-induced RAD51 foci, but has little effect on RPA32 accumula-
tion (Figures 7A–7D), confirming that it discriminates BRCA1-
dependent from BRCA1-independent steps leading to HR.
Moreover, these findings separate an unappreciated require-
ment for substrate recognition by the BRCA1 tBRCT in DNA
end-resection and ssDNA generation at damage sites, from
the events that trigger RAD51 recruitment to those sites, with im-
plications for the biology of BRCA1 aswell as the development of
selective chemical modulators of its function.
DISCUSSION
Intracellular signaling cascades initiated by protein kinases are
critical to cellular physiology, and often perturbed in human dis-
eases. ATP-competitive inhibitors of protein kinase activity that
are currently used to modulate these signaling cascades for
mechanistic analysis or disease therapy frequently induce pleio-
tropic effects by suppressing multiple pathways downstream of
the inhibited enzyme. The work we report here exemplifies an
alternative strategy to selectively interrupt kinase signaling
cascades, by blocking the protein-protein interactions between
phosphorylated protein substrates and their cognate recogni-
tion domains that propagate kinase-initiated signals. In partic-
ular, we have identified Bractoppin, a drug-like chemical inhibi-
tor of phosphopeptide substrate recognition by the human
BRCA1 tBRCT domain. Our findings have several important
implications.
The BRCA1 tBRCT domain represents a prominent member of
a vital family comprising >200 phosphopeptide-binding domains
that mediate kinase-initiated signaling pathways from bacteria to
humans, but remain refractory to selective, non-peptidic inhibi-
tors despite much recent effort. By characterizing and experi-
mentally validating a structural model for the interaction between
Bractoppin and the BRCA1 tBRCT, our findings open avenues to
target other members of this family. We provide evidence that
Bractoppin not only engages residues in BRCA1 tBRCT that
recognize the phosphopeptide substrate, but also occupies
two additional hydrophobic pockets that are not explored by(B) The percentage of cells with 4N DNA content representing G2/M phases of
representative of three independent repeats. Statistical significance was tested u
(C) Percentage of viable cells relative to untreated controls measured using calce
and viability wasmeasured 7 days later. The bars show unirradiated cells (Control)
Tet-inducible BRCA1 tBRCT expression (bars 3, 4), or 1–100 mM Bractoppin (ba
while compounds were added 1 hr before. Results are representative of three
comparisons test post one-way ANOVA. *p% 0.05; ***p% 0.001.
Error bars represent standard deviation from the mean.
10 Cell Chemical Biology 25, 1–14, June 21, 2018the phosphopeptide. These hydrophobic pockets are absent in
structurally related tBRCT domains such as those of MCPH1
or MDC1. Moreover, other structurally related tBRCT domains
found in ECT2 or TOPBP1 1/2 exhibit an altered orientation be-
tween the two individual BRCT modules that occludes Bractop-
pin binding. Compounds designed to validate the structure-ac-
tivity relationships of Bractoppin provide plausible starting
points from which to identify inhibitors that engage these related
domains. Together, our findings suggest a structural rationale for
the experimentally observed in vitro selectivity of Bractoppin for
BRCA1 tBRCT, and also provide a blueprint for the design of new
inhibitors selective for other members of the BRCT domain
family.
Several lines of evidence indicate that Bractoppin selectively
inhibits in the cellular milieu substrate recognition by BRCA1
tBRCT. Bractoppin engages its target in cells as detected by
an unimolecular FRET biosensor designed to report inhibition
of BACH1 phosphopeptide recognition. It selectively inhibits
the recruitment of BRCA1 protein to cellular sites of DNA dam-
age, an event mediated by the protein-protein interactions of
the BRCA1 tBRCT domain. But it has little effect on the recruit-
ment of MDC1 or TOPBP1 via their structurally related tBRCT
domains.
The selectivity of Bractoppin’s effects is further attested by
the phenotypes triggered by overexpression of the BRCA1 or
MDC1 tBRCT domains, which are predicted to mimic the ac-
tion of chemical inhibitors by competitively suppressing the
protein-protein interactions of endogenous BRCA1 or MDC1.
While BRCA1 tBRCT overexpression suppresses BRCA1
recruitment to damage-induced foci, MDC1 tBRCT overex-
pression diminishes both MDC1 and BRCA1 recruitment.
Our results speak not only to the biological selectivity of sub-
strate recognition via members of the tBRCT domain family,
but also the potential to modulate intracellular signaling with
equivalent precision through the development of selective
inhibitors.
Of note, however, Bractoppin exhibits nanomolar on-target
potency in vitro, but elicits cellular effects only at 10–100 mM,
suggesting that compound exposure may be variously limited
by uptake, stability or metabolism in different cell types. This
observation highlights limitations to be addressed by future
chemical optimization and biological studies.
Human BRCA1 normally plays a vital tumor suppressive role by
acting as the hub of a macromolecular assembly formed on
damaged DNA, which transmits intracellular signals to activate
the G2 cell-cycle checkpoint, and also to regulate reactions that
lead to the error-free repair of damagedDNAbyRAD51-mediated
HR. HR is initiated by the endonucleolytic resection of broken
dsDNA ends into overhanging ssDNA, which involves BRCA1
tBRCT-dependent macromolecular complexes containing thethe cell cycle corresponding to the treatment conditions as in (A). Results are
sing Dunnett’s multiple comparisons test, post one-way ANOVA. ***p% 0.001.
in AM dye and cell counting (mean ± SD, n = 3). Cells were irradiated with 1 Gy,
, or cells exposed to 1Gy, without (bars 1, 2), or with additional treatments using
rs 5–10). Tet-induced BRCA1 tBRCT expression was for 6 hr before radiation,
independent repeats. Statistical analysis was done using Dunnett’s multiple
(legend on next page)
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generation at dsDNA breaks owing to the existence of alterna-
tive, BRCA1-independent mechanisms. In contrast, BRCA1
inactivation diminishes the assembly of the RAD51 recombina-
tion enzyme on ssDNA substrates generated by end-resection,
likely through its ability to form complexes with the HRmediators
PALB2 and BRCA2 (reviewed in San Filippo et al., 2008; Syming-
ton and Gautier, 2011; Venkitaraman, 2014). Indeed, while Brac-
toppin suppresses the enforcement of the G2 checkpoint for
DNA damage, as well as the assembly of RAD51 at damage
sites, it spares ssDNA generation marked by the ssDNA-binding
protein, RPA32. Thus, the effects of Bractoppin on signals
evoked by DNA damage endorse its selectivity for BRCA1-
dependent steps.
Diminished RAD51 foci formation at sites of DNA damage
typically signifies the suppression of DNA repair by HR (re-
viewed in San Filippo et al., 2008), suggesting that Bractoppin
inhibits this repair mechanism. BRCA1 is, however, implicated
in multiple events during the sensing, signaling, and repair of
different forms of DNA damage, warranting future characteriza-
tion of the effects of Bractoppin on HR and other mechanisms
for DNA repair.
Our results collectively provide proof-of-concept for a strategy
to selectively interrupt intracellular signaling pathways initiated
by protein kinases using drugs that block the molecular recogni-
tion of phosphorylated proteins. The recent finding that inhibitors
of the protein-protein interactions of the phosphopeptide-bind-
ing Polo-box domains of Polo-like kinases can be used to target
KRASmutant cancers (Narvaez et al., 2017) speaks to the future
therapeutic potential for such a strategy.
Our finding that Bractoppin enhances the cell-killing effects
of IR suggests one such therapeutic avenue. The majority of
patients with solid tumors receive therapeutic radiation, but
tumor recrudescence and off-target effects remain major clin-
ical problems. Radiation-sensitizing agents may alleviate such
issues by decreasing the radiation dosage required for total
tumor clearance. In addition, it has also been suggested that
inhibitors of BRCA1 may sensitize tumor cells to the effect of
targeted therapies such as PARP1 inhibitors. But because
the systemic administration of BRCA1 inhibitors combined
with PARP1 inhibitors is likely to induce PARP1 inhibitor sensi-
tivity even in normal tissues, we are skeptical about the thera-
peutic index of such an approach. Aside from cancer therapy
using BRCA1 tBRCT inhibitors, however, the potential utility of
selective tBRCT inhibitors in the treatment of other diseases
remains relatively under-explored. For example, the develop-
ment of selective targeting tBRCT domains in bacterial pro-
teins that mediate DNA replication or genome maintenance
may open potential applications in the treatment of infections.Figure 7. Bractoppin Selectively Interrupts BRCA1-Dependent Steps in
(A) Confocal images depicting at high magnification the recruitment of the RPA
carried out as described as in Figure 5A. Staining in the upper row is for RPA32 (gr
green staining, with DNA staining (DAPI) in blue. Scale bar represents 10 mm.
(B) Recruitment of RAD51 protein into nuclear foci, measured and depicted as d
(C) Percentage of cells positive for radiation-induced nuclear RPA32 foci (mean ±
3,500, CCBT2047) enumerated by high-content imaging (see the STAR Method
***p% 0.001. Similar results were observed in three independent repeats.
(D) Percentage of cells containing nuclear RAD51 foci enumerated and depicted
12 Cell Chemical Biology 25, 1–14, June 21, 2018The work we report here represents an initial step to the future
exploration of such strategies.SIGNIFICANCE
The development of Bractoppin exemplifies a strategy to
chemically inhibit phosphopeptide substrate recognition
by BRCT domains, evolutionarily conserved mediators of
genome maintenance pathways from prokaryotes to eu-
karyotes. The structure-activity relationships of Bractoppin
open avenues to selectively target other members of this
domain family, which are attractive, but currently inacces-
sible, targets for drug discovery against human diseases.
Unlike ATP-competitive inhibitors of DNA damage-activated
protein kinases, Bractoppin preferentially inhibits BRCA1
tBRCT-dependent steps in the DNA damage response.
Thus, our work illustrates a new approach to selectively
interrupt intracellular signaling pathways initiated by protein
kinases using drugs that block the molecular recognition of
phosphorylated proteins.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING














B Molecular Dynamic (MD) Simulations
B Protein Expression and Purification
B Fluorescence Polarization (FP) Assay
B Alpha Screen Assay
B Microscale Thermophoresis (MST)
B Unimolecular FRET Sensor Assay
B Immunofluorescence Staining for Damage-
Induced Foci
B Cell Cycle Profiles
B Cell Viability Assays
d QUANTIFICATION AND STATISTICAL ANALYSISA Repair by Homologous Recombination
rotein into nuclear foci after the indicated treatments. Experiments were
), middle row, for mCherry-BRCA1 tBRCT (red); lower row, merged red and
ribed in (A). Scale bar represents 10 mm.
; n = 5,300, 0 Gy; 3,200, 16 Gy; 3,600, BRCA1 tBRCT; 3,400, Bractoppin;
tatistical significance was performed using an unpaired two-tailed t test.
described in (B). ***p% 0.001.
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Antibodies
Anti-BRCA1 (D9) Santa Cruz Biotech Catalog No: sc-6954, RRID: AB_626761
Anti-BRCA1 (OP92) EMD Millipore Catalog No: OP92, RRID: AB_10682944
Anti-Rad51 Novus Biologicals Catalog No: NB100-148, RRID: AB_10002131
Anti-MDC1 Bethyl Labs Catalog No: A300-051A, RRID: AB_203282
Anti-RPA32/RPA2 Abcam Catalog No: ab2175, RRID: AB_302873
Goat-anti-mouse Alexa 488 Invitrogen Catalog No: A11001, RRID: AB_2534069
Goat-anti-rabbit Alexa 488 Invitrogen Catalog No: A11034, RRID: AB_2576217
Bacterial and Virus Strains
E. coli BL21(DE3) NEB Catalog No: C2527I
E. coli BL21(DE3*) Thermo Fisher Catalog No: C6010-03
E. coli C41(DE3) Lucigen Catalog No: 60442-1
Chemicals, Peptides, and Recombinant Proteins
Bractoppin This study N/A
CCBT2047 This study N/A
TAMRA_GGSRSTpSPTFNK-NH2 Designer Bioscience N/A





ESIYFpTPELYDPEDT-NH2 Designer Bioscience N/A
PSpYVNVQN-NH2 Designer Bioscience N/A
SILSDIpSFDKTDEpSLDWDSSLE-NH2 Designer BioScience N/A
KKATQpSQEY Designer Bioscience N/A
TKSVAEpTPVHK Designer Bioscience N/A
BRCA1 tBRCT (residues 1646-1859) This study N/A
GRB2 SH2 (residues 55-152) This study N/A
ECT2 BRCT 0/1/2 (residues 22-326) This study N/A
MCPH1 tBRCT 2/3 (residues 640-835) This study N/A
TOPBP1 BRCT1/2 (residues 1-290) This study N/A
TOPBP1 tBRCT 7/8 (residues 1264–1493) This study N/A
pET28a Vector EMD Biosciences Catalog No: 69864-3
pGEX-4T-3 GE Healthcare Catalog No: 28-9545-52
LB HI media Catalog No: M575
Kanamycin sulfate Amresco Catalog No: 0408
Chloramphenicol Amresco Catalog No: 0230
Tris - HCl Fischer Scientific Catalog No: 15965
EDTA Fischer Scientific Catalog No: 12635
IPTG Sigma Catalog No: 15002
Imidazole Merck Catalog No: 104716
PMSF Amresco Catalog No: 97064-898-EA
DTT Sigma Catalog No: 43815
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Lysozyme Sigma Catalog No: L6876
Protease inhibitor cocktail tablet Roche Catalog No: 11697498001
Sodium chloride Hi Media Catalog No: MB023-1
Sodium di-hydrogen phosphate Hi Media Catalog No: TC068-1KG
SDS Page Precast gels Biorad Catalog No: 4561033
DMSO Merck Catalog No: 102952
Tween-20 Sigma Catalog No: P2287
Glycerol Fischer Scientific Catalog No: 11005
3 color pre-stained protein ladder Puregene Catalog No: PG-PMT2962
Calcein AM Thermo Fisher Scientific Catalog No: C3100MP
DAPI Sigma Catalog No: D9542
Thymidine Acros Organics Code: 226740250
Doxycycline hyclate Sigma Catalog No: D9891
Mowiol 40-88 Sigma Catalog No: 324590
Hygromycin B Thermo Fisher Scientific Catalog No: 10687010
Blasticidin InvivoGen Catalog Code: ant-bl
Zeocin Thermo Fisher Scientific Catalog No: R25001
Critical Commercial Assays
MICROPLATE, 384 WELL, PP, F-BOTTOM, BLACK, Greiner Bio-One Catalog No: 781209
Anti-6xHis Alpha LISA Acceptor beads PerkinElmer Part No: AL128C
AlphaScreen Streptavidin Donor beads PerkinElmer Part No: 6760002S
96 well plates, half-area white plates Corning Catalog No: CLS3642
Monolith NT Protein Labeling Kit RED- NHS Nanotemper Catalog No: L001
Monolith NT.115 MST Premium Coated Capillaries Nanotemper Catalog No: MO-K005
Experimental Models: Cell Lines
HEK Parental (Flp-In T-REx 293) Thermo Fisher Scientific Catalog No: R78007
CAL-51 cells Leibniz Institute DSMZ-German
Collection of Microorganisms
and Cell Cultures, GmbH
DSMZ No: ACC302 (DSMZ)
Recombinant DNA
pcDNA5/FRT/TO Invitrogen Catalog No: V6520-20
pOG44 Invitrogen Catalog No: V6005-20
pcDNA5/FRT/TO-mCherry-BRCT(tBRCA1) GeneArt N/A
pcDNA5/FRT/TO- mCherry-BRCT(tMDC1) GeneArt N/A
pReceiver-C-HaloTag-BRCA1 [NM_007294.3] GeneCopoeia Catalog No: EX-H0047-M50
Software and Algorithms
Schro¨dinger small molecule drug discovery
suite (Schro¨dinger Release 2015-3]
Schro¨dinger https://www.schrodinger.com/suites/
small-molecule-drug-discovery-suite
Pymol Ver:1.7.4 Schro¨dinger https://www.schrodinger.com/suites/pymol
HCS Studio 2.0 Thermo Fisher Scientific Catalog No: SX000041A
Other
96 well imaging plates Eppendorf Catalog No: 0030741030
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Compounds
Compounds were synthesized by O2h Discovery (Ahmedabad, India), and validated by liquid chromatography coupled to mass
spectrometry (LC/MS) and 1H-NMR. Synthetic methods are provided below under Method Details. All compounds were >95%
pure as determined by high-performance liquid chromatography (HPLC). Stock solutions were prepared from dry powder in
100% DMSO at 50mM concentration. For primary screens by FP, an initial stock solution of 5mM compound in 100%
DMSO was diluted to 125uM in 2% DMSO. For Alpha assays, 5x concentrations of each of the half-logarithmic dilutions of
the compound in 100% DMSO were diluted to the indicated assay concentrations in 2% DMSO. For MST assays, stock so-
lutions were diluted to the indicated assay concentrations in 2% DMSO. For cell-based experiments, 20mM stocks of Brac-
toppin and CCBT2047 in 100% DMSO were diluted in growth media (DMEM supplemented with 10%FBS, 2mM Glutamine)
to the indicated concentrations (0.5% DMSO final concentration), thoroughly mixed, and spun at 13,000rpm for 10 seconds
before use.
Antibodies
Antibodies used for immunofluorescence analysis at the indicated dilutions were: BRCA1 (sc-6954, Santa Cruz Biotech, 1:600),
BRCA1 (OP92, EMD Millipore, 1:200), MDC1 (A300-051A, Bethyl Labs, 1:250), RPA32/RPA2 (ab2175, Abcam, 1:250), Rad51
(NB100-148, Novus Biologicals, 1:1000), Histone H3 (Ser10] (ab5176, Abcam, 1:200). For the Western blotting analysis of protein
expression in stable clones, mCherry antibody (GTX128509, GeneTex) was used at 1:2000.
Expression Constructs
Tetracycline (Tet)-inducible plasmids encoding mCherry fused to either wild-type of mutant BRCA1 or MDC1 tBRCT domains were
prepared in the pcDNA5/FRT/TO-mCherry vector by gene synthesis (GeneArt, Regensburg, Germany). Briefly, synthetic polynucle-
otides encoding SV40-NLS (3X)-BRCA1 tBRCT (aa 1620-1862) or SV40-NLS (3X) MDC1 tBRCT (aa 1875-2089) were cloned between
the BamH1 and XhoI restriction sites of the vector. The unimolecular FRET biosensor was also synthesized. Briefly, Tag-BFP was
attached N-terminally to a BACH1 (aa 985-1000) peptide containing the Ser990 phosphosite, and C-terminally to 3x SV40-NLS, fol-
lowed by the BRCA1 tBRCT domain (aa 1643-1862) and Tag-GFP2 (Figure 4A).
Cell Lines and Cell Culture
The Flp-In T-REx 293 Cell Line was procured from Thermo Fisher Scientific (R78007) and maintained in DMEM supplemented
with 10%FBS, 2mM L-glutamine, Blasticidin (15mg/ml) and Zeocin (100mg/ml) at 37Cwith 5%CO2. Stable cell lines were generated
by co-transfecting pOG44 with pCDNA5/FRT/TO vectors encoding the gene of interest (see Expression constructs) in a 9:1 ratio us-
ing FuGENE HD transfection reagent (E2311, Promega). After 10 days of selection using Blasticidin (15mg/ml) and Hygromycin
B (50mg/ml), viable colonies were expanded, and assayed for the loss of b-galactosidase activity and Zeocin resistance to identify
clones with stable integration of plasmid. Protein expression was induced with Doxycycline (1mg/ml for 48 h). CAL-51 cells (main-
tained in DMEM supplemented with 10%FBS, 2mM L-glutamine at 37C with 5% CO2) were transfected with a construct encoding
wild-type full-length human BRCA1, and a single-cell clone (CAL-51 clone 60) isolated by neomycin selection was used for further
studies. Both the Flp-In T-REx 293 and CAL-51 clone 60 cells were authenticated at the DNA Forensics Laboratory Pvt. Ltd.,
New Delhi, India using short tandem repeat (STR) profiling at the 8 core loci plus amelogenin specified by Capes-Davies et al.
(2013). Flp-In T-REx 293 cells were confirmed to be female, and were an exact match (15/15 alleles) for the HEK-293 (CRL-
1573) human cell line in the reference database. CAL-51 clone 60 cells were also confirmed to be female, and were an 80% match
(12/15 alleles) with the CAL-51 human cell line in the reference database confirming relatedness (Capes-Davies et al., 2013), and
consistent with mutational drift and microsatellite instability observed in CAL-51 cells during passage in culture (Seitz et al., 2003;
Gorringe et al., 2005).
Cell Irradiation
Cells were irradiated to the indicated doses using either the Blood Irradiator 2000 with Cobalt-60 (Board of Radiation and Isotope
Technology, Department of Atomic Energy, Government of India) at an effective dose rate of 3.9Gy/min, or with an X-ray generator
(Xstrahl, RS225) at a dose rate of 1.5Gy/min.
METHOD DETAILS
Where applicable, information concerning replication of experiments, the sample size analysed, and the statistical method used for
comparisons is provided in the figure legends.
Chemical Synthesis
Detailed methods for compound synthesis are as follows.Cell Chemical Biology 25, 1–14.e1–e12, June 21, 2018 e3
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BRCA1-Dependent Signaling, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.02.012Synthesis of Bractoppin: (4- (2-fluorobenzyl)piperazin-1-yl) (2-phenyl-1H-benzo[d]imidazol-6-yl) methanoneSynthesis of methyl 2-phenyl-1H-benzo[d]imidazole-6-carboxylate: In a vial the mixture of benzoic acid (0.367 g), methyl 3,4-dia-
minobezoate (0.5 g) and PPA (2 g) was heated to 170C for 3 h, TLC ( MDC : MeOH = 9:1) indicated that starting material was
consumed. The reaction mixture was poured into saturated NaHCO3 solution followed by extraction with ethyl acetate
(20mL x 3). The combined organic phase was washed with brine (30mL x 2), dried with anhydrous Na2SO4, filtered and concentrated
in vacuum to afford methyl 2-phenyl-1H-benzo[d]imidazole-6-carboxylate (0.12 g, crude) obtained as an off-white solid.
Synthesis of 2-phenyl-1H-benzo[d]imidazole-6-carboxylic acid: The mixture of methyl 2-phenyl-1H-benzo[d]imidazole-6-carbox-
ylate (0.1 g), concentrated HCl (7 mL), acetic acid (6 mL) was heated to 90C for 3 h, TLC (MDC:MeOH = 9:1) indicated that starting
material was consumed. The reaction mixture was neutralized by saturated NaHCO3 solution followed by extraction with ethyl ac-
etate (20mL x 3). The combined organic phasewaswashedwith brine (30mL x 3), dried with anhydrous Na2SO4, filtered and concen-
trated in vacuum to afford methyl 2-phenyl-1H-benzo[d]imidazole-6-carboxylatic acid (0.07 g, crude) obtained as an off-white solid.
Synthesis of (4-(2-fluorobenzyl) piperazin-1-yl) (2-phenyl-1H-benzo[d] imidazol-6-yl) methanone: To a solution of methyl 2-phenyl-
1H-benzo[d]imidazole-6-carboxylic acid (0.07 g) in DMF was added 1- (2-fluorobenzyl) piperazine (0.06 g) and HATU (0.17 g). Reac-
tion mixture was cooled to 0-5C followed by the addition of DIPEA (0.1 mL) and stirred at same temperature for 2 h, TLC (MDC:
MeOH = 9:1) indicated that both starting materials were consumed. Reaction mixture was poured into water followed by extraction
with ethyl acetate (10mL x 3). The combined organic phase was washed with brine (40mL x 2), dried with anhydrous Na2SO4, filtered
and concentrated in vacuum to afford crude which was purified by flash chromatography where the product eluted at 3% MeOH in
MDC to afford of (4- (2-fluorobenzyl)piperazin-1-yl) (2-phenyl-1H-benzo[d] imidazol-6-yl) methanone (0.035 g). LCMS: (M+H+): 415.3.
1H NMR: DMSO-d6 400MHz d: 13.132 (s, 1H), 8.198-8.180 (d, J = 7.2 Hz, 2H), 7.708-7.667 (m, 1H), 7.586-7.726 (m, 4H), 7.446-7.412
(t, J = 6.8 Hz, 1H), 7.341-7.324 (d, J = 6.8 Hz, 1H), 3.581 (s, 3H), 2.442 (s,1H), 1.225 (s,1H), HPLC Purity; 100%
Synthesis of CCBT2009: (4- (2-fluorobenzyl)piperazin-1-yl) (2-isopropyl-1H-benzo[d]imidazol-6-yl) methanonee4 Cell Chemical Biology 25, 1–14.e1–e12, June 21, 2018
Please cite this article in press as: Periasamy et al., Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt
BRCA1-Dependent Signaling, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.02.012Synthesis of methyl 2-isopropyl-1H-benzo[d]imidazole-6-carboxylate: In a vial the mixture of isobutyric acid (0.15 g),
methyl 3,4-diaminobezoate (0.3 g) and PPA (2 g) was heated to 170C for 3 h, TLC (MDC:MeOH = 9:1) indicated that starting
material was consumed. Reaction mixture was poured into saturated NaHCO3 solution followed by extraction with ethyl ac-
etate (20 mL x 4). The combined organic phase was washed with brine (10 mL x 2), dried with anhydrous Na2SO4, filtered and
concentrated in vacuum to afford methyl 2-isopropyl-1H-benzo[d]imidazole-6-carboxylate (0.45 g, crude) obtained as an off-
white solid.
Synthesis of methyl 2-isopropyl-1H-benzo[d]imidazole-6-carboxylic acid: The mixture of methyl 2-isopropyl-1H-benzo[d]imid-
azole-6-carboxylate (0.45 g), concentrated HCl (7 mL), acetic acid (6 mL) was heated to 90C for 3 h, TLC (MDC : MeOH = 9:1) indi-
cated that starting material was consumed. Reaction mixture was neutralized by saturated NaHCO3 solution (pH7) followed by
extraction with ethyl acetate (20 mL x 4). The combined organic phase was washed with brine (10 mL x 3), dried with anhydrous
Na2SO4, filtered and concentrated in vacuum to afford methyl 2-isopropyl-1H-benzo[d]imidazole-6-carboxylic acid (0.24 g, crude)
obtained as an off-white solid.
Synthesis of (4- (2-fluorobenzyl)piperazin-1-yl) (2-isopropyl-1H-benzo[d]imidazol-6-yl) methanone: To a solution of 2-isopropyl-
1H-benzo[d]imidazole-6-carboxylic acid (0.24 g) in DMF (5 mL) was added 1- (2-fluorobenzyl) piperazine (0.228 g), HATU (0.67 g).
Reaction mixture was cooled to 0C-5C followed by addition of DIPEA (0.4 mL) and stirred at same temperature for 2 h, TLC
(MDC: MeOH = 9:1) indicated that both starting materials were consumed. Reaction mixture was poured into water followed by
extraction with ethyl acetate (10 mL x 3). The combined organic phase was washed with brine (100 mL x 2), dried with anhydrous
Na2SO4, filtered and concentrated in vacuum to afford CCBT2009 (0.015g) obtained as white solid after purification by preparative
HPLC. LCMS: (M+H+): 381.40. 1H NMR: DMSO-d6 400 MHz d: 12.434 (s, NH), 7.516-7.495 (d, J = 8.4 Hz, 2H), 7.465-7.429
(t, J = 7.2 Hz, 1H) 7.363-7.349 (d, J = 5.6 Hz, 1H), 6.556 (s, 1H), 3.214-3.110 (m,1H), 2.544 (s, 2H), 1.355-1.338 (d, J = 6.8 Hz, 6H).
HPLC Purity; 99.54%
Synthesis of CCBT2029: (4- (2-fluorobenzyl)piperazin-1-yl) (1H-indol-6-yl)methanoneTo a solution of indole 5-carboxylic acid (0.5 g, 3.0 mmol) in DMF (10 mL) was added HATU (2.35 g, 6.1 mmol), DIPEA (1.19 g,
9.2 mmol) at 0C, and further added 1- (2-fluorobenzyl)piperazine (0.72 g, 3.7 mmol) and stirred at room temperature for 1 h, TLC
(Chloroform: Methanol = 9:1) indicated the starting material was consumed. The reaction mixture was poured into cold water and
extracted with ethyl acetate. The combined organic phase waswashedwith brine (100mL x 2), dried with anhydrous Na2SO4, filtered
and concentrated in vacuum to afford the crude which was purified by flash chromatography where the product eluted at 65% ethyl
acetate in hexane to give (4- (2-fluorobenzyl)piperazin-1-yl) (1H-indol-6-yl)methanone (0.3 g) obtained as light yellow oil. HPLC
Purity; 99.39%
Synthesis of CCBT2047: (4-isobutylpiperazin-1-yl)(2-phenyl-1H-benzo[d]imidazol-5-yl) methanoneTo a solution of 2-phenyl-1H-benzo[d]imidazole-6-carboxylic acid (0.1 g, 0.42 mmol, 1.0 eq) in DMF (5 mL) was added
EDC.HCl (0.08 g, 0.46 mmol, 1.1 eq) and HoBt (0.02 g, 0.21 mmol, 0.5 eq) and stirred at room temperature for 30 min. To
this N-isobutylpiperazine (0.06 g, 0.42 mmol, 1.0 eq) and DIPEA (0.2 mL, 1.26 mmol, 3.0 eq) was charged. The mixture was
stirred at room temperature for 18 h, TLC (CHCl3: MeOH = 9:1) indicated the starting material was consumed. Reaction mixture
was poured into water followed by extraction with ethyl acetate (30 mL*3). The combined organic phase was washed with brine
(40 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford the crude which was purified by flash
chromatography where the product eluted at 3.5% MeOH in chloroform followed by trituration with n-pentane to afford the
product (0.022g) as light brown solid. LCMS: (M+H+): 363.4. 1H NMR: DMSO-d6 400 MHz d: 13.127 (s, 1H), 8.202-8.183
(d, J= 7.6Hz, 2H), 7.713-7.673 (t, J= 8.0Hz, 2H), 7.592-7.504 (m, 4H), 7.277-7.211 (q, J= 18Hz, 1H), 3.508 (broad s, 4H),
2.362-2.332 (t, J= 10Hz, 4H), 2.077-2.063 (d, J= 5.6Hz, 2H), 1.793-1.777 (broad d, J= 6.4Hz, 1H), 0.871-0.861 (d, J= 4.0Hz,
6H), HPLC Purity; 98.83%Cell Chemical Biology 25, 1–14.e1–e12, June 21, 2018 e5
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BRCA1-Dependent Signaling, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.02.012Synthesis of CCBT2082: (4-(2-fluorobenzyl)piperazin-1-yl)(2-(pyridin-4-yl)-1H-benzo[d]imidazol-5-yl)methanoneSynthesis of methyl 2-(pyridin-4-yl)-1H-benzo[d]imidazole-6-carboxylate: To a solution of methyl 3,4-Diaminobenzoate (0.284 g,
2.406 mmol, 1.0 eq) in DMF (12 mL) were added Pyridine-4-carboxaldehyde (0.4 g, 2.647 mmol, 1.1 eq) and oxone (0.962 g,
1.564 mmol, 0.65 eq) at room temperature. The mixture was stirred at room temperature for 2 h, TLC (Hexane: Ethylacetate = 5:5)
indicated the starting material was consumed. The mixture was poured on to the saturated NaHCO3 solution (20 mL) followed by
extraction with ethyl acetate (100 mL*2). The combined organic phase was washed with brine (30 mL*2), dried with anhydrous
Na2SO4, filtered and concentrated in vacuum to afford the product (0.5g, crude) as light yellow solid.
Synthesis of 2-(pyridin-4-yl)-1H-benzo[d]imidazole-6-carboxylic acid:A solution of methyl 2-(pyridin-4-yl)-1H-benzo[d]imidazole-
6-carboxylate (0.3 g) in concentrated HCl (5mL) and acetic acid (5mL) was heated at 90C for 3 h, TLC (Dichloromethane: Methanol=
9:1) indicated that starting material was consumed. The reaction mixture was concentrated under vacuum and the traces acetic acid
was further removed by azeotropic distillationwith dichloromethane (10mL). The obtained solid was dried under vacuum to afford the
product (0.280 g, crude) as brown solid
Synthesis of (4-(2-fluorobenzyl)piperazin-1-yl)(2-(pyridin-4-yl)-1H-benzo[d]imidazol-5-yl) methanone: To a solution of 2-(pyridin-4-
yl)-1H-benzo[d]imidazole-6-carboxylic acid (0.190 g, 0.771 mmol, 1.5 eq) in DMF (5 mL) were added HATU (0.590 g, 1.543 mmol,
3.0 eq) and DIPEA (0.400 g, 3.087 mmol, 6.0 eq) at 0C. The reaction mixture was stirred at 0C for 30 min. 1-(2-fluorobenzyl)piper-
azine (0.1 g, 0.514mmol, 1.0 eq) was added in to the reactionmixture and stirred at room temperature for 2 h, TLC (Dichloromethane:
Methanol= 9:1) indicated that both starting materials were consumed. The reaction mixture was poured in to the saturated NaHCO3
solution (30 mL) and product was extracted by ethyl acetate (50 mL*3). The combined organic phase was washed with brine
(100 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford crude. This crude material was purified
by flash chromatography where the product eluted at 7%methanol in chloroform. The pure product fraction was concentrated under
vacuum to afford the product (0.04 g, pure) as off white solid. LCMS: (M+H+): 416.3. 1H NMR: DMSO-d6 400 MHz d: 13.512 (s, 1H),
8.786 (d, J=5.2 Hz, 2H), 8.117 (d, J=5.2 Hz, 2H), 7.592-7.786 (m, 2H), 7.433 (t, J = 7.2 Hz, 1H), 7.159-7.380 (m, 4H), 3.410-3.810
(m, 6H), 2.350-2.510 (m, 4H), HPLC Purity; 97.65%
Synthesis of CCBT2084: (4-(2-fluorobenzyl)piperazin-1-yl)(2-morpholino-1H-benzo[d]imidazol-5-yl) methanoneSynthesis of methyl 2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate: To a solution of Methyl-3,4-diaminobenzoate (1.5 g,
9.02mmol, 1.0 eq) in DMF (5mL) was addedCDI (2.2 g, 13.54mmol, 1.5 eq) at room temperature. The reactionmixture was heated at
100C for 1 h, TLC (100%Ethyl acetate) indicated the startingmaterial was consumed. The reactionmixture was poured into ice-cold
water and obtained precipitates were collected by filtration, washedwith distilled water and dried to affordmethyl 2-oxo-2,3-dihydro-
1H- benzo[d]imidazole-5-carboxylate (1.52 g, pure).
Synthesis of methyl 2-chloro-1H-benzo[d]imidazole-5-carboxylate: A suspension of methyl 2-oxo-2,3-dihydro-1H-benzo[d]imid-
azole-5-carboxylate (1.5 g) in POCl3 (15 mL) was heated at 120
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NaHCO3 solution (50ml). The resulting precipitates were collected by filtration, washed with distilled water and dried to afford methyl
2-chloro-1H-benzo[d]imidazole-5-carboxylate (1.38 g, pure).
Synthesis of methyl 2-morpholino-1H-benzo[d]imidazole-6-carboxylate: Methyl 2-chloro-1H-benzo[d]imidazole-5-carboxylate
(0.367 g, 1.0 eq) and morpholine (2 mL) was heated at 150C for 3 h, TLC (100% Ethyl acetate) indicated that starting material
was consumed. The reactionmixture was poured into water followed by extraction with 10%MeOH inMDC (20mL*3). The combined
organic phase was washed with water (30 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The obtained
crude material was purified by flash chromatography, where the product was eluted at 80% EtoAc in Hexane. The obtained product
fraction was concentrated under vacuum to afford methyl 2-morpholino-1H-benzo[d]imidazole-6-carboxylate (0.1 g, pure) as light
yellow liquid.
Synthesis of 2-morpholino-1H-benzo[d]imidazole-6-carboxylic acid: A solution of methyl 2-morpholino-1H-benzo[d]imidazole-6-
carboxylate (0.1 g) in concentrated HCl (0.6 mL) and acetic acid (0.6 mL) was heated to 120C for 3 h, TLC (Dichloromethane: Meth-
anol= 9:1) indicated that starting material was consumed. The reaction mixture was concentrated under vacuum and the traces ace-
tic acid was further removed by azeotropic distillation with dichloromethane (50 ml). The obtained solid was dried under vacuum to
afford the product (0.11 g, crude) as light yellow solid.
Synthesis of (4-(2-fluorobenzyl)piperazin-1-yl)(2-morpholino-1H-benzo[d]imidazol-5-yl) methanone: To a solution of 2-morpho-
lino-1H-benzo[d]imidazole-6-carboxylic acid (0.1 g, 0.4 mmol, 1.0 eq) in DMF (5 mL) were added 1-(2-fluorobenzyl)piperazine
(0.08 g, 0.4 mmol, 1.0 eq) and HATU (0.155 g, 0.48 mmol, 1.2 eq) at 0C. The reaction mixture was stirred for 10 min and DIPEA
(0.160 g, 1.2mmol, 3.0 eq) was added at 0C. Themixture was stirred at room temperature for 3 h, TLC (Dichloromethane: Methanol=
9:1) indicated the starting material was consumed. Reaction mixture was poured into water followed by extraction with ethyl acetate
(30mL*3). The combined organic phasewaswashedwith brine (40mL*2), dried with anhydrous Na2SO4, filtered and concentrated in
vacuum to afford the crude which was purified by prep-HPLC purification using NH4HCO3 as buffer to afford (4-(2-fluorobenzyl)pi-
perazin-1-yl)(2-morpholino-1H-benzo[d]imidazol-5-yl) methanone (0.030 g) as white solid. LCMS: (M+H+): 424.45. 1H NMR:
DMSO-d6 400 MHz d: 11.799 (br, s, 1H), 7.410-7.480 (m, 1H), 7.310-7.390 (m, 1H), 7.165-7.243 (m, 4H), 7.003-7.022 (d, J= 7.2 Hz
1H), 3.718-3.741 (m, 4H), 3.349-3.650 (m, 12 H), 2.381-2.500 (m, 4H), HPLC Purity; 100%
Synthesis of CCBT2106: (4-(4-hydroxybenzyl)piperazin-1-yl)(2-phenyl-1H-benzo[d] imidazole-6-yl)methanoneTo a solution of (2-phenyl-1H-benzo[d]imidazol-6-yl)(piperazin-1-yl)methanone (0.3 g, 0.877 mmol, 1.0 eq) and 4-hydroxybenzal-
dehyde (0.160 g, 1.315 mmol, 1.5 eq) in methanol (5 mL) were added TEA (0.132 g, 1.315 mmol, 1.5 eq) and acetic acid (5 drops) at
room temperature. The reaction mixture was stirred at room temperature for 1 h. Sodiumcyanoborohydride (0.273 g, 4.385 mmol,
5.0 eq) was added in to the reaction mixture and stirred for 20 h, TLC (Chloroform: Methanol= 9:1) indicated the starting material
was consumed. Reaction mixture was poured into ice cold water and extracted with ethyl acetate (50 mL*3). The combined organic
phasewaswashedwith brine (30mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford the crudewhich
was purified by prep-HPLC purification using NH4HCO3 as buffer to afford the product (0.90 g) as off white solid. LCMS: (M+H
+):
413.2. 1H NMR: DMSO-d6, 400 MHz d: 13.031 (s, 2H), 8.180-8.231 (m, 4H), 7.504-7.643 (m, 5H), 7.237 (dd, J=1.2 Hz, J=8.4 Hz,
1H), 7.093 (d, J=8.4 Hz, 2H), 6.707 (d, J = 8.4 Hz, 2H), 3.430-3.580 (m, 4H), 2.303-2.445(m, 4H).
Synthesis of CCBT2107: (4-(4-methylbenzyl)piperazin-1-yl)(2-phenyl-1H-benzo[d] imidazol-6-yl)methanoneTo a solution of (2-phenyl-1H-benzo[d]imidazol-6-yl)(piperazin-1-yl)methanone (0.25 g, 0.728 mmol, 1.0 eq) and 4-methylbenzal-
dehyde (0.096 g, 0.801 mmol, 1.1 eq) in DCM (5 mL) were added TEA (0.110 g, 1.092 mmol, 1.5 eq) and acetic acid (5 drops) at room
temperature. The reaction mixture was stirred at room temperature for 1 h. Sodium triacetoxyborohydride (0.461 g, 2.184 mmol,
3.0 eq) was added in to the reaction mixture and stirred for 20 h, TLC (Chloroform: Methanol= 9:1) indicated the starting material
was consumed. Reaction mixture was poured into ice cold water and extracted with ethyl acetate (50 mL*3). The combined organic
phase was washed with brine (30 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford the crude
which was purified by prep-HPLC purification using NH4HCO3 as buffer to afford the product (0.050 g) as off white solid.Cell Chemical Biology 25, 1–14.e1–e12, June 21, 2018 e7
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Synthesis of CCBT2905: (R)-(4-(2-fluorobenzyl)-2-isopropylpiperazin-1-yl)(2-methyl-1H-benzo[d]imidazol-5-yl)methanoneTo a stirred solution of 2-Methyl-1H-benzimidazole-5-carboxylic acid (0.6g, 3.4mmol, 1.0 eq) in DMF (20mL) was added EDC.HCl
(0.71g, 3.9mmol, 1.1 eq) followed by HOBT (0.23g, 1.7mmol, 0.5 eq) under N2 gas atmosphere at room temperature and stirred for
30 min. The resulting reaction mixture was added (R)-1-(2-fluorobenzyl)-3-isopropylpiperazine (0.925g, 3.9mmol, 1.15 eq) at room
temperature and stirred for 20h. TLC (9:1; chloroform; methanol) indicated the starting material was consumed. The reacting mixture
was poured into water and extracted with ethyl acetate (35ml x 3). The organic layers were combined and washed with water, dried
over anhydrous sodium sulphate and concentrated under reduced pressure to afford provide crude product, which was purified by
preparative HPLC. LCMS: (M+H+): 395.5. 1H NMR:CDCl3 400MHz d: 12.326-12.378 (d, J = 20.8 Hz, 1H), 7.438 (br, 2H), 7.306-7.359
(m, 2H), 7.153-7.206 (m, 2H), 7.066-7.118 (m, 1H), 4.218 (br, 1H), 3.503-3.566 (t, J = 6 Hz, 3H) , 3.274-3.348 (br, 1H), 2.942 (br, 2H),
2.683 (s, 1H), 2.336-2.405 (br, 1H), 2.179(br, 1H), 1.968-1.998(d, J = 12 Hz, 1H), 0.826-0.892 (br, 4H), 0.502-0.648 (br, 2H), HPLC Pu-
rity; 96.13%. Note: CCBT2906 was synthesized from (S)-1-(2-fluorobenzyl)-3-isopropylpiperazine and 2-Methyl-1H-benzimidazole-
5-carboxylic acid using similar protocol. HPLC Purity; 100%
Synthesis of CCBT2907: (4-(2-fluorobenzyl)piperazin-1-yl)(2-methyl-1H-benzo[d]imidazol-5-yl)methanoneTo a stirred solution of 2-Methyl-1H-benzimidazole-5-carboxylic acid (0.5g, 2.8mmol, 1.0 eq) in DMF (10mL) were added EDC.HCl
(0.6 g, 3.11 mmol, 1.1 eq) followed by HOBT (0.19 g, 1.4mmol, 0.5 eq) under N2 atmosphere at room temperature and stirred for
30 min. The resulting reaction mixture was added 1-(2-fluorobenzyl)piperazine (0.63g, 3.2mmol, 1.15 eq) at room temperature
and stirred for 20 h. TLC (9:1; chloroform; methanol) indicated the starting material was consumed. The reacting mixture was poured
into water and extracted with ethyl acetate (35 ml x 3). The organic layers were combined and washed with water, dried over anhy-
drous sodium sulphate and concentrated under reduced pressure to afford crude S2907 which was purified preparative HPLC.
LCMS: (M+H+): 353.5; 1H NMR: 12.382 (d, J = 4.8 Hz, 1H), 7.496-7.528 (m, 1H), 7.409-7.44 (m, 2H), 7.306-7.362 (m, 1H), 7.113-
7.205 (m, 3H), 3.573 (s, 3H), 3.510 (br, 3H), 2.420 (br, 4H), HPLC Purity; 99.94%
Synthesis of CCBT2908: 5-((4-(2-fluorobenzyl)piperazin-1-yl)methyl)-2-methyl-1H-benzo[d]imidazoleTo a stirred solution of CCBT2907 (0.3 g, 0.852 mmol, 1.0 eq) in THF (6mL) was added LiAlH4 (0.85 mL, 2 M in THF, 0.34 mmol,
4.0 eq) at 0C under N2 atmosphere, and the resulting reaction mixture was stirred for 3h at room temperature. As observed on
TLC, 50% of CCBT2907 remained unconsumed along with the formation of CCBT2908. Hence, the resulting reaction mixture
was further added LiAlH4 (0.85 mL, 2M in THF, 0.34mmol, 4.0 eq) at 0
C, and further heated to 50C for 5h. TLC (9:1; chloroform;
methanol) indicated the startingmaterial was consumed. The resulting reactionmixture was poured in to water and the aqueous layer
was extracted with ethyl acetate (25mL x 3). The combined organic layer was then washed with brine, dried over anhydrous sodium
sulphate and concentrated under reduced pressure to provide crude which was purified by preparative HPLC. LCMS: (M+H+):
338.22. 1H NMR: CDCl3 400 MHz d: 12.073 (s, 1H), 7.281-7.319 (m, 3H), 7.131-7.184 (m, 2H), 7.018-7.038 (d, J = 8 Hz, 1H), 3.512
(s, 4H), 2.457-2.517 (m, 3H), 2.296-2.387 (m, 6H), HPLC Purity; 99.45%e8 Cell Chemical Biology 25, 1–14.e1–e12, June 21, 2018
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Binding mode determination was undertaken using the Glide program from the Schro¨dinger small molecule drug discovery suite
(Schro¨dinger Release 2015-3). For human BRCA1 tBRCT, unliganded (PDB: 1JNX) and peptide-bound (PDB: 3K0K) forms were
superimposed, processed (by adding hydrogen, fixing bond orders, fixing missing atoms and residues, determining and fixing pro-
tonation states of side chains) before energetic minimisation of the whole complex using OPLS2005 force field with a maximum
permitted rmsd of 0.30 A˚. This procedure was carried out using the protein preparation wizard of Maestro 10.3. To dock compounds,
the bound peptide and water molecules were deleted. A grid box of size 22 x 27 x 22 A˚3 with an inner box (10 x 15 x 10 A˚3) centred at
X, Y, Z coordinates -21.0, 11.0 and -25.0 was generated that covers the pS-P-T-F residues with default parameters and no con-
straints. Ligands were drawn and prepared using LigPrep. Ionisation and tautomeric states were carefully selected after inspection.
Five conformers were generated for each ligand using Confgen with an OPLS2005 forcefield and a minimum rmsd cutoff of 1.0 A˚.
Each conformer was then individually docked using the Glide SP protocol, to identify the 10 best poses per ligand. In case of primary
screen hits, poses from all the conformers were clustered and each cluster pose was carefully inspected to explain structure activity
relationships between analogs.
Molecular Dynamic (MD) Simulations
MD simulations for the complex were carried out using all-atom optimized potential for liquid simulations (OPLS-AA) force field im-
plemented in GPU-accelerated Desmond software (Schro¨dinger Release 2015-3). Simulations were conducted with a TIP3P explicit
solvent model and periodic boundary condition. With 1.2 ps recording intervals, a 5 ns simulation was performed under NPT
ensemble with temperature fixed at 300 K and pressure at 1.01 bar. The RESPA integration time step was set at 2 fs and all other
parameters including the equilibration stepwere assigned the default settings available in theMolecular Dynamicswizard ofMaestro.
Post-simulation analyses were all performed within Desmond software.
Protein Expression and Purification
Synthetic gene constructs encoding the GRB2 SH2 domain (residues 55-152), or the BRCT domains of different human proteins
(BRCA1 tBRCT residues 1646-1859, TOPBP1 tBRCT 7/8 residues 1264–1493, TOPBP1 BRCT 1/2 residues 1-290, ECT2 BRCT res-
idues 22-326, MCPH1 tBRCT 2/3 residues 640-835) fused N-terminally to 6x Histidine residues, and codon optimized for expression
in E. coli, were procured from GeneArt (Regensburg, Germany) in the pET28a expression vector. All constructs were expressed in
E. coli BL21(DE3) cells grown in LB medium containing 50mg/mL Kanamycin.
BRCA1 tBRCT: 6x His- BRCA1 tBRCT expression was induced in BL21(DE3) strain at 0.6-0.8 OD600 with 0.25mM isopropyl b-D-1-
thiogalactopyranoside (IPTG) and the culture was grown for 16 h at 18C. Cells were harvested and the pellet was suspended in ice
cold lysis buffer (50mM Tris HCl [pH 7.5], 400mMNaCl, 0.1mM PMSF, 1mMDTT, and 1 protease inhibitor tablet (Roche)). Cells were
lysed by sonication on ice and centrifuged at 20,000 rev min-1 for 30 min at 4C to remove cell debris. The supernatant was applied
onto a HisTrap HP column (GE Healthcare) pre-equilibrated with a buffer (50mM Tris HCl [pH 7.5], 400mM NaCl, 1mM DTT, and
25mM Imidazole). The column was washed with same buffer until all unbound proteins were removed. The protein of interest was
eluted using a linear gradient of up to 100% elution buffer (50mM Tris HCl [pH 7.5], 400mMNaCl, 1mM DTT, and 500mM Imidazole).
Protein purity was visualized by running SDS-PAGE. Fractions of sufficient purity were pooled and concentrated to 2 ml using a
10 kDa cutoff Centricon centrifugal filter devices (Millipore). The concentrated protein was further purified using HiLoad 16/600
Superdex-75 prep-grade gel-filtration column (GE Healthcare) pre-equilibrated with 20mM Tris HCl [pH 7.5], 100mM NaCl and
1mMDTT. TOPBP1 tBRCT 7/8: A similar procedure was used as for BRCA1 tBRCT, except that: (a) protein expression was induced
in BL21(DE3*) strain at 0.6 OD600 with 0.2mM IPTG and the culture was grown for 16 h at 18
C, (b) lysis buffer was 50mM Sodium
Phosphate [pH-7.5], 300mMNaCl, 0.1mMPMSF, 1mMDTT, 0.1mg/ml Lysozyme, and 1 protease inhibitor tablet, (c) HisTrap column
was pre-equilibrated with 50mM Sodium Phosphate [pH-7.5], 300mM NaCl and 20mM Imidazole, and (d) column was eluted with
50mM Sodium Phosphate [pH-7.5], 300mM NaCl and 500mM Imidazole. TOPBP1 tBRCT 0/1/2: A similar procedure was used as
for BRCA1 tBRCT, except that: (a) protein expression was induced at 1.0 OD600 with 0.4mM IPTG and the culture was grown for
16 h at 18C, (b) lysis buffer was 20mM Sodium Phosphate [pH-7.5], 500mM NaCl, 0.1mM PMSF, 1mM DTT, 0.1mg/ml Lysozyme,
and 1 protease inhibitor tablet, (c) HisTrap column was pre-equilibrated with 20mM Sodium Phosphate [pH-7.5], 500mM NaCl and
20mM Imidazole, and (d) column was eluted with 20mM Sodium Phosphate [pH-7.5], 500mM NaCl and 500mM Imidazole. ECT2
BRCT: A similar procedure was used as for BRCA1 tBRCT, except that: (a) protein expression was induced in C41(DE3) strain at
1.2 OD600 with 1mM IPTG and the culture was grown for 24 h at 14
C, (b) lysis buffer was 50mM HEPES [pH 7.5], 150mM KCl,
100mM PMSF, 10mM Imidazole and 1 protease inhibitor tablet, (c) HisTrap column was pre-equilibrated with 50mM HEPES [pH
7.5], 150mMKCl, 10mM Imidazole and 1mMDTT, and (d) column was eluted with 50mMHEPES [pH 7.5], 150mMKCl, 500mM Imid-
azole and 1mM DTT, (e) the protein was further purified by anion-exchange chromatography (Mono-Q 10/100 GL, GE Healthcare)
with a NaCl gradient (0–1.0 M NaCl in 50 mMHEPES [pH 8.0]), and (f) the concentrated protein was loaded on HiLoad 16/600 Super-
dex-75 prep-grade gel-filtration column (GE Healthcare) pre-equilibrated with 50mM HEPES [pH 7.5], 150mM KCl and 1mM DTT.
MCPH1 tBRCT 2/3: A similar procedure was used as for BRCA1 tBRCT, except that: (a) protein expression was induced at
0.6 OD600 with 0.25mM IPTG and the culture was grown for 16 h at 18
C, (b) lysis buffer was 20mM Sodium Phosphate [pH-7.5],
500mM NaCl, 0.1mM PMSF, 1mM DTT and 1 protease inhibitor tablet, (c) HisTrap column was pre-equilibrated with 20mM Sodium
Phosphate [pH-7.5], 500mMNaCl and 20mM Imidazole, and (d) column was eluted with 20mMSodium Phosphate [pH-7.5], 500mMCell Chemical Biology 25, 1–14.e1–e12, June 21, 2018 e9
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induced at 0.6 OD600 with 0.25mM IPTG and the culture was grown for 16 h at 18
C, (b) lysis buffer was 50mM Tris HCl [pH 8.0],
500mM NaCl, 100mM PMSF, 5mM beta mercaptoethanol, 10mM Imidazole and 1 protease inhibitor tablet, (c) HisTrap column
was pre-equilibrated with 50mM Tris HCl [pH 8.0], 500mM NaCl, 5mM beta mercaptoethanol and 10mM Imidazole, and (d) column
was eluted with 50mM Tris HCl [pH 8.0], 150mM NaCl, 5mM beta mercaptoethanol and 500mM Imidazole. Fractions of sufficient
purity were pooled and concentrated to 2 ml using a 3 kDa cutoff Centricon centrifugal filter device (Millipore).
Fluorescence Polarization (FP) Assay
FP reactions were conducted in black 384well plates using the TECAN FreedomEVO 200 dispenser (Tecan). We dispensed 3xwork-
ing concentrations of BRCA1 tBRCT protein and TAMRA-labeled BACH1 peptide, 10ml each prepared in assay buffer (20mM Tris
buffer pH 7.4, 200mM NaCl, 0.05% Tween-20, 2mM DTT) to achieve final concentrations of 75nM and 10nM, respectively. 10 ml
of compound at a final concentration of 125mMwas added to the plate and incubated for 20 min at room temperature. Relative fluo-
rescence wasmeasured using the TECAN infinite M1000 Promicroplate reader using an excitation wavelength 530 nm, and an emis-
sion wavelength of 610 nm. The degree of polarization was expressed in millipolarization units (mP) as calculated by the reader soft-
ware using fluorescence intensities parallel and perpendicular with the plane of linearly polarized excitation light. 1%DMSO controls
were used. Test compounds were assayed in triplicate. Percent inhibition was calculated to express compound activity after normal-
ising to controls.
Alpha Screen Assay
We tested 6x-Histidine-tagged BRCA1 tBRCT, TOPBP1 tBRCT 7/8 or GRB2 SH2, and their cognate biotinylated peptide substrates.
Initial checkerboard titrations were carried out to determine the optimal concentration of protein and peptide for each screen. Assays
were conducted in Costar 96-well flat bottom white polystyrene plates using assay buffer (20mM Tris buffer pH 7.4, 200mM NaCl,
0.05% Tween-20, 2mM DTT). 5x-working concentrations of the reagents were dispensed in 10ml each in the order: 6x-Histidine
tagged protein, biotinylated peptide, test compound. Plates were incubated at room temperature for 20 min and 10 ml each of nickel
chelate AlphaLISA acceptor beads and AlphaScreen Streptavidin donor beads (both from Perkin Elmer) at a final concentration of
20 mg/ml were added. Plates were covered with adhesive seals and incubated in the dark for 1 h at 25C. The AlphaScreen signal
was read using TECAN infinite M1000 Pro microplate reader at excitation wavelength 680nm and emission wavelength 520-620nm.
1% DMSO controls were run in parallel, and used to calculate percent inhibition. A 10-point dose response was performed in trip-
licate to determine IC50 values for each compound.
Microscale Thermophoresis (MST)
Protein domains used in the assay were labeled with NT-647-NHS fluorescent dye using the Monolith NTTM Protein Labeling Kit
(NanoTemper Technologies). Assays were carried out in 20mM Tris buffer, pH 7.4, with 200mM NaCl, 0.05% Tween-20 and 2mM
DTT. For the direct binding assay, 10ml of labeled protein at a final concentration of 20nM was mixed with 10ml of test compound
and incubated on ice for 10 min. For the competitive assay, 10ml of labeled protein at a final concentration of 20nM was mixed
with 2mM cognate peptide substrate at the EC80 concentration determined by prior titration using a 16-point serial dilution by
direct-binding MST. For both assays, samples prepared as above were centrifuged at 15000 rpm at 4C for 10 min and 4ml of the
supernatant was loaded into premium glass capillaries (NanoTemper Technologies). MST analysis was performed at MST power
of 40% and LED power of 80%, at 22C temperature using a Monolith NT.115 (NanoTemper Technologies). An initial ‘‘Capillary
Scan’’ was performed to scan for fluorescence across the length of the capillary tray to determine the exact position of each capillary
before the MST measurement was started. Test compounds were assayed at 16 different concentrations by serial dilution, and data
were analysed using NanoTemper analysis software. Kd values were determined using ‘‘T-jump + Thermophoresis’’ settings. The
change in thermophoresis between different experimental conditions was expressed as the change in the normalized fluorescence
(DFnorm), which is defined as Fhot/Fcold (F-values correspond to average fluorescence values between defined areas in the curve un-
der steady-state conditions under control (Fcold) or experimental (Fhot) conditions. Titration of the non-fluorescent ligand causes a
gradual change in thermophoresis, which is plotted as DFnorm to yield a binding curve, which was then fitted to derive binding
constants.
Unimolecular FRET Sensor Assay
HEK293 cells expressing the stably integrated FRET sensor in a tetracycline-inducible system were used. 3.5x105 cells/35mm dish
were seeded in Matrigel coated plates and expression was induced using doxycycline (1mg/ml) for 48 h. Cells were incubated with
compounds for 24 h in serum containing media at 100mM final concentration with 0.5% DMSO. Where indicated, mCherry-BRCA1
tBRCT constructs were transiently transfected in a 4.5:1 ratio of Fugene:DNA and incubated in serum-containing media for 24 h (Fu-
gene HD transfection reagent, Promega). Two h after 16 Gy IR, cells were washed in 1x PBS (pH 7.4) and fixed in 4% PFA at room
temperature (RT) for 10’. Cells were mounted with Mowiol (without anti-fade) before imaging. The following excitation and emission
wavelengths were used: Ex 402nm / Em 457nm for Tag-BFP; Ex 483nm / Em 506nm for Tag-GFP2 and Ex 594nm / Em 610nm for
mCherry. Two methodologies were adapted to calculate FRET efficiencies: Sensitized Emission (SE) and Acceptor Photobleaching
(AP). Images acquired as noted below were quantified using HCS studio 2.0 (Thermo Fisher Scientific) to define nuclear morphology
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ing a 40x oil objective. For spectral corrections Tag-BFP and Tag-GFP2 constructs were used independent from the FRET biosensor.
Corrections for the extent of spectral cross-talk were calculated and applied as follows (M€uller et al., 2013).
Emission crosstalk of constructs encoding the acceptor or donor alone into the FRET channels was calculated as Co-efficient
A and Co-efficient B respectively using the following formulae:
Acceptor in FRET channel (Co-efficient A) = Average intensity of Acceptor only using FRET filter set / Average intensity of Acceptor
only using acceptor filter set
Donor in FRET channel (Co-efficient B) = Average intensity of Donor only using FRET filter set / Average intensity of Donor only
using donor filter set.
Corrections using the two coefficients were then applied to the FRET efficiency equation: FRET efficiency = FRET – (Coefficient A *
FRET biosensor using Acceptor filter set] – (Coefficient B * FRET biosensor using Donor filter set].
Data was then represented as% FRET efficiency of mean nuclear intensities from300-600 cells per experiment and represented
as mean ± SEM.
For acceptor photobleaching FRET measurements, images were independently acquired for donor and acceptor fluorophore
channels before acceptor photobleaching using an LSM780 confocal microscope with a 40x oil objective. A region of interest
(ROI) was selected within the nucleus and the acceptor was bleached forR10 cycles to ensureR60% bleaching efficiency. After
effective photobleaching, images were again acquired for both donor and acceptor channels and then FRET efficiencies were calcu-
lated (Paster et al., 2009) bymeasuringmean nuclear intensities obtained using high-content image analysis software HCS studio 2.0
using this formula:
FRET efficiency = (BFP post-bleach – BFP pre-bleach) / BFP post-bleach.
Data were normalized for bleach efficiencies and plotted from 300-600 cells per experiment and represented as mean ± SEM.
Immunofluorescence Staining for Damage-Induced Foci
HEK293 cells stably harboring plasmids for Tet-inducible expression of tBRCT domains were seeded at 30,000 cells/well on Matri-
gel-coated 96-well plates, and treated as indicated. Cells were fixed in 2.5% PFA, for 20’ at RT and incubated in 1x PBS with 10%
FBS plus 0.5% TritonX-100 for 1 h for blocking and permeabilization. Primary antibody staining was performed at the indicated di-
lutions in PBST-BSA buffer (0.7mg/ml BSA, 0.05% Tween-20 in 1XPBS) for 1h at RT. Cells were then extensively washed in PBST-
BSA buffer and stained with goat-anti-mouse Alexa 488 secondary antibody (Invitrogen), at 1:1000 dilution along with 2.5mg/ml DAPI
for nuclear staining. CAL-51 clone 60 cells were stained similarly, except that prior fixing, cells were pre-extracted, with CSK buffer
[10mM PIPES [pH 6.8], 100mM NaCl, 300mM Sucrose, 3mM MgCl2, 1mM EGTA, 0.5% TritonX100] for 5 minutes in ice and stained
with Anti-BRCA1 (Ab-1) (MS110) [OP92, 1:200, Millipore] using procedure as mentioned above. For RPA32 staining, an additional
step of pre-extraction with 0.4% NP-40 was done before fixation. Images were acquired on a high-content imaging platform (Cello-
mics ArrayScan VTI HCS Reader (Thermo Fisher Scientific)) using a 40x objective. On average 800 fields from 6-well replicates,
containing a total of 10-20K cells were imaged per treatment group and quantified using image analysis software (in-house algo-
rithms usingMatLab and commercially available HCS studio 2.0 from Thermo Fisher Scientific). Briefly, nuclear objects were defined,
and foci were enumerated for each of the different DDR proteins. Plots were generated to compare control (0 Gy) and 16Gy irradiated
samples for foci number vs. percentage of cells. Cut-off values for foci number per cell specifying the maximal difference between
control and irradiated samples were determined to calculate the percentage of cells positive for radiation-induced foci. These cut-off
values were used to enumerate changes in the percentage of cells positive for radiation-induced foci with or without inhibitor treat-
ment. Representative images at high magnification showing clusters of foci-bearing cells were taken using a Zeiss LSM780 confocal
microscope with a 63x oil objective and 3x optical zooming.
Cell Cycle Profiles
HEK293 cells stably harboring plasmids for Tet-inducible expression of tBRCT domains were seeded on 12-well plates at
1.8 X105 cells/well. Cells were thymidine blocked and synchronously released into the cell cycle following irradiation at 4Gy, without
or with exposure to compounds (at final concentrations with 0.5% DMSO) in serum-containing media for 16 h. Cells were re-sus-
pended in 1x PBS, fixed with 80% ethanol, and permeabilized in buffer containing 0.1% Tween-20 in PBS (PBST), for 20’ at RT.
DAPI staining was used to quantify nuclear DNA content. Analysis was performed using a Beckman Coulter Gallios analyzer, and
quantified using the Dean-Jet algorithm in FlowJo software.
Cell Viability Assays
HEK293 cells stably harboring plasmids for Tet-inducible expression of tBRCT domains were seeded at a density of 60,000 cells/
35mm dish. Compound addition or inducible expression of BRCA1 tBRCT were performed as indicated, when cells were 30%
confluent, before exposure to 1Gy irradiation. Cells were replenished with media every 3rd day for 7 days, re-suspended in cell disso-
ciation buffer, which was neutralized in 1x PBS. Cells weremixed thoroughly to ensure single cell suspension before measurement of
viability using Calcein AM dye and/or cell counting with a hemocytometer. Cell survival fractions were measured using fluorescence
readout of Calcein AMwith the Tecan Infinite M1000 Pro reader (485nm excitation and 515nm emission) and data were normalized to
untreated controls across treatment groups.Cell Chemical Biology 25, 1–14.e1–e12, June 21, 2018 e11
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All data fitting and statistical analyses were performed using GraphPad version 6.05 for Windows (GraphPad Software Inc, www.
graphpad.com). No methods were used to determine whether the data met assumptions of the statistical approach. All the
experiments were performed at least with three independent repeats and represented as mean ± Standard deviation. Descriptions
of samples, and the exact values of n, are provided in the figure legends. Statistical significance was tested using an unpaired, two
tailed t-test. *** P%0.001e12 Cell Chemical Biology 25, 1–14.e1–e12, June 21, 2018
